Y-mAbs Therapeutics, Inc. - Bathi operasional EBITDA YMAB

The EBITDA_Co valuation displayed on GURU.Markets demonstrates that the figure stands at . Y-mAbs Therapeutics (YMAB) is implementing AI for molecule creation and robotizing drug synthesis. The business relies on proprietary antibody delivery protocols for pediatric neurosurgery. The monopoly position of the drug Danyelza in treating neuroblastoma and strict FDA oversight ensure a steady patient inflow and protection of the orphan segment.

Analyzing the calculated EBITDA allows for an assessment of the financial stability of Y-mAbs Therapeutics (YMAB) as a reputable developer of antibodies for pediatric oncology. This indicator captures real cash flow through market trade-offs; however, acquiring the asset at the peak of the curve creates a risk of overpayment and capital freeze, which is critical for evaluating the fundamental value of a biotechnology business.